Table 2 Use of LT4 formulations
From: Thyroid hormone use in clinical practice by Israeli endocrinologists: a THESIS* questionnaire survey
Tablets | Soft-gel capsules | Liquid solution | No change with formulations | Only tablets available in Israel | No reply | |
|---|---|---|---|---|---|---|
Which LT4 preparations would you prescribe for: | ||||||
Patients with variable absorption due to interfering drugs? | 36 (29.3%) | 4 (3.3%) | 7 (5.7%) | 25 (20.3%) | 48 (39.0%) | 3 (2.4%) |
Patients with possible celiac disease, malabsorption, lactose intolerance, or intolerance to common excipients? | 60 (48.8%) | 1 (0.8%) | 5 (4.1%) | 8 (6.5%) | 47 (38.2%) | 2 (1.6%) |
Patients with established on generic T4 who have unexplained poor biochemical control of hypothyroidism | 52 (42.3%) | 4 (3.3%) | 6 (4.9%) | 12 (9.8%) | 45 (36.6%) | 4 (3.3%) |
Patients with poor control who is unable to separate LT4 from food / drink? | 41 (33.3%) | 1 (0.8%) | 10 (8.1%) | 17 (13.8%) | 48 (39.0%) | 6 (4.9%) |
Patients with established generic LT4 therapy who have good biochemical control but continues to have symptoms? | 43 (35.0%) | 1 (0.8%) | 3 (2.4%) | 32 (26.0%) | 42 (34.1%) | 2 (1.6%) |